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Purpose: To evaluate the role of interleukin-6 (IL-6) in the inflammatory and proliferative stages of Eales’ disease (ED)
and to determine the influence of IL-6–174G/C polymorphism in the IL-6 and IL-6-regulated protein expression, as well
as the development of ED.
Methods: One hundred and twenty-one patients diagnosed with ED, 223 matched healthy controls, and 16 control patients
with macular holes were recruited from the eastern Indian population. Serum and vitreous levels of IL-6 and vascular
endothelial growth factors (VEGF) were measured by enzyme-linked immunosorbent assay. Serum levels of high-
sensitivity C-reactive protein (hsCRP) were measured by enzyme immunoassay. Subjects were genotyped for the IL-6–
174G/C polymorphism (rs1800795) by a custom TaqMan single-nucleotide polymorphism (SNP) Genotyping Assays
system.
Results: Serum IL-6 (p<0.0001), hsCRP (p<0.0001), and VEGF (p=0.0031) levels were significantly higher in the
inflammatory stage of ED than in healthy controls. Serum IL-6 also significantly correlated with hsCRP (Spearman’s
correlation coefficient; r=0.4992, p=0.0009), but not with VEGF in this stage in ED patients. At the proliferative stage of
ED, significantly higher levels of vitreous IL-6 (p=<0.0001) and VEGF (p=<0.0001) were found compared with the
vitreous of patients with macular holes. A significant correlation was observed between vitreous IL-6 and VEGF in ED
patients (Spearman’s correlation coefficient; r=0.5834, p=0.0087). A statistically significant association was found
between the −174GG genotype (p=0.006) and occurrence of ED. Mean serum and vitreous concentrations of IL-6 were
also higher in the subjects with the GG genotype than in those with the GC or CC genotype in this population.
Conclusions: IL-6 expression, regulated by the allelic distribution of −174 loci and the enhanced level of IL-6, modulates
CRP and VEGF concentration depending respectively on the acute inflammatory stimulation at the initial stage and
angiogenic stimulation at the advanced stage of ED.
Eales’  disease  (ED)  is  an  idiopathic  inflammatory
vasoproliferative disease of the retina primarily affecting the
peripheral retina of individuals in the third and fourth decade
of  life  [1,2].  It  is  predominantly  found  in  the  Indian
subcontinent [3]. The etiopathogenesis of this disease still
remains an open experimental issue, but pathologically it is
characterized by retinal perivasculitis mainly affecting the
peripheral retina (inflammatory stage), leading to sclerosis of
the retinal vessels indicating retinal ischemia (ischemic stage),
and  finally  retinal  neovascularization,  recurrent  vitreous
hemorrhage, with or without retinal detachment (proliferative
stage) [3,4]. The association of human leukocyte antigen [5]
and T-cell involvement in the lymphocytic infiltration in the
epiretinal membrane of patients with ED [6] indicate that the
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T-cell-mediated immune mechanism might play a key role in
retinal vasculitis i.e., the inflammatory stage of this disease.
Interleukin-6 (IL-6) is a multifunctional cytokine with a
proinflammatory character, and is thought to be one of the
major mediators in driving the acute phase immune response
[7]. IL-6, produced by cells of the innate and adaptive immune
system, induces B-cell growth and differentiation [8], and act
as an early mediator of acute phase inflammatory proteins,
such  as  C-reactive  protein  (CRP)  expression  [9,10]  and
contributes to the activation and /or proliferation of T cells
[9,11]. Several studies have suggested that assessments of
IL-6  and  CRP  are  valuable  tools  for  predicting  systemic
inflammation in different pathologic conditions [12,13]; these
two proteins were also elevated in ED pathogenesis [14-16].
IL-6  is  also  considered  to  be  an  indirect  inducer  of
angiogenesis through the induction of vascular endothelial
growth factor (VEGF) [17,18], a potent angiogenic factor
[19]  involved  in  several  pathological  angiogenesis  in  the
retina including ED [15,20].
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2552The  effect  of  cytokines  generated  during  the
inflammatory  stage  of  ED  [14]  clearly  indicates  their
involvement in the proliferative stage, i.e., the severity of this
disease and variation in cytokine production in all probability
affects the extent and severity of the disease. As the magnitude
of cytokine production does not depend only on antigenic
challenge but also on host genetic factors [21], the search for
single-nucleotide polymorphism (SNP) has now become a
potential  tool  not  only  for  better  understanding  of  the
etiopathogenesis of the disease, but also as a probable marker
of  disease  susceptibility  and  severity.  It  has  been
demonstrated  that  IL-6  promoter  polymorphisms  are  key
regulators of IL-6 gene and downstream protein levels in vitro
and in vivo [22]. Polymorphism of position −174 is one of the
several  IL-6  polymorphisms  that  have  been  suggested  to
affect IL-6 expression [23], and has been investigated in a
wide variety of diseases. Therefore, this polymorphism may
be  predisposing  factor  for  the  development  of  ED  in  an
individual.
This study was conducted to investigate whether IL-6 acts
as a modulator in the inflammatory and proliferative stages of
ED by regulating expression of acute phase inflammatory
protein and potent angiogenic factor, respectively, as well as
to determine the influence of IL-6–174G/C polymorphism in
the IL-6 and/or IL-6-regulated protein expression and the
development of ED.
METHODS
Study  subjects:  One  hundred  and  twenty-one  patients  (97
males, 24 female) with ocular findings suggestive of ED,
representing different stages of the disease, were recruited
from  a  retina  research  clinic  at  the  Regional  Institute  of
Ophthalmology,  Kolkata,  India  between  2007  and  2010.
Forty-one  patients  presented  with  active  vasculitis  in  the
periphery of the retina, 50 patients had neovascularization in
the periphery, and 30 patients had developed an advanced
stage of neovascularization in the disc and periphery with
vitreous hemorrhage and tractional retinal detachment.
Ophthalmological  diagnosis  was  performed  for  all
patients by dilated fundus examination with direct and indirect
ophthalmoscopy, slit lamp biomicroscopy with +90D and 3-
mirror  lens,  stereoscopic  color  fundus  photography  and
fluorescein  angiography.  Eyes  exhibiting  vitreous
hemorrhage underwent ultrasonography to detect tractional
retinal detachment. Other detailed ophthalmic examinations
included  visual  acuity  determination  by  Early  Treatment
Diabetic  Retinopathy  Study  (ETDRS)  chart,  intraocular
pressure measurement by applanation tonometry, and anterior
segment evaluation by slit lamp examination. The location
and extent of retinal involvement by vasculitis, nonperfusion,
neovascularization,  and  fibrovascular  traction  were
documented  in  all  patients  by  digital  color  fundus
photography and fluorescein angiography.
As ED is characterized by retinal phlebitis, peripheral
nonperfusion,  and  retinal  neovascularization,  fundus
examination reveals a different clinical picture according to
the stage of disease progression that patients present.
In  relation  to  the  inflammatory  stage,  phlebitis  was
manifested in the patients of our study as venous dilation with
tortuosity  and  discontinuity  of  veins  with  flame  shaped
hemorrhages  and  perivascular  exudates  along  peripheral
veins. Vascular sheathing was found in some patients in a few
or more vessels ranging from continuous thin white lines to
segmental heavy exudation. The number of patients in the
inflammatory  stage  was  low  in  this  study  due  to  less
attendance of these patients to the hospital, as they are usually
asymptomatic regarding loss of vision, which is a subjective
phenomenon. Moreover, patients usually report when they
have a marked loss of vision due to vitreous hemorrhage from
new blood vessels or in the advanced proliferative stage when
they  have  lost  perception  of  light.  Some  patients  in  the
proliferative stage of ED present neovascularization of the
disc,  whereas  some  exhibit  neovascularization  elsewhere,
located at the junction of perfused and nonperfused retina. In
others,  where  vitreous  hemorrhage  has  already  occurred,
fundus details are usually obscured, but old vitreous bleed
leading  to  fibrous  organization,  retinitis  proliferans,  and
subsequently tractional retinal detachment may be seen.
Among those patients who were in the proliferative stage
(80 patients), 19 of them had undergone pars plana vitrectomy
and undiluted vitreous was collected from these patients for
selective protein study.
Sixteen patients (15 males, 1 female) who underwent
vitrectomy and internal tamponade for idiopathic macular
holes were included in this study as control for vitreous study.
This disorder is caused by vitreomacular traction occurring
before posterior vitreous detachment and there are no signs of
ischemia, proliferation, or inflammation.
Two hundred twenty three (183 males, 40 females) age-
and  sex-matched  healthy  adults,  without  any  history
suggestive of ED, attending the outpatient department of the
same  institute  for  treatment  of  visual  difficulty  due  to
refractive  errors  without  any  other  systemic  or  ocular
pathology. provided the blood samples and constituted our
healthy control group.
Subjects with a history of diabetes mellitus, hypertension,
collagen  vascular  disease,  HIV,  symptomatic  arthritis,
symptomatic  malignancy,  sarcoidosis,  Behcet’s  disease,
systemic lupus erythematosus, Coats’ disease, and syphilis
were excluded from the study. The study protocol according
to the declaration of Helsinki was approved by Institution’s
Ethical Committee and informed consent was obtained from
each subject.
Sample  collection  and  preparation  for  analysis:  Ten
milliliters  of  whole  blood  from  ED  patients  and  healthy
controls  were  collected  by  venipuncture  from  peripheral
Molecular Vision 2011; 17:2552-2563 <http://www.molvis.org/molvis/v17/a276> © 2011 Molecular Vision
2553veins. Seven milliliters of blood were taken in an EDTA-
containing tube for peripheral blood mononuclear cell layer
separation. The other 3 ml were collected in a clot vial and
allowed to clot. After clot retraction, serum was separated by
centrifugation at 3,000× g at 4 °C for 20 min and was frozen
at −80 °C until further use.
Vitreous samples were collected from the study subjects
and  control  patients  who  underwent  three-port  pars  plana
vitrectomy. After the construction of the ports, a vitreous
cutter was introduced in the mid-vitreous; before turning the
infusion fluid, 200 μl of undiluted vitreous gel was excised
and aspirated into the handheld sterile syringe attached to the
suction port of the vitrectomy probe, using manual suction
with a high cutting rate. The vitreous biopsy samples thus
obtained  were  immediately  put  in  ice  and  centrifuged  at
10,000×  g  for  15  min  at  4  °C.  After  centrifugation,
supernatants were divided into two equal aliquots and stored
at −20 °C for immediate use or at −80 °C for future use.
Simultaneously venous blood was collected from the study
subjects and control patients, who underwent vitrectomy, at
the time of vitrectomy and processed as stated above.
Genomic  DNA  isolation  and  genotyping  of  interleukin-6–
174G/C  (rs1800795)  polymorphism:  Genomic  DNA  was
isolated  from  peripheral  blood  mononuclear  cells  by
proteinase-K digestion and the standard high salt extraction
method [24]. Genotyping of the −174G/C polymorphism in
the 5′ regulatory region of the IL-6 gene in the patient and
healthy control groups was performed by a custom TaqMan
SNP Genotyping Assay system on the 7300 ABI Real-Time
PCR system (both from Applied Biosystems, Foster City, CA)
using 96 well plates. The sequences of forward and reverse
primers and two probes for the −174C and −174G alleles are
listed in Table 1.
Measurement  of  interleukin-6,  high-sensitivity  C-reactive
protein,  and  vascular  endothelial  growth  factor
concentration: Total concentrations of IL-6 and VEGF in the
serum and vitreous of study subjects were measured using a
commercial enzyme-linked immunosorbent assay kit (R&D
System,  Inc.,  Minneapolis,  MN),  with  a  minimal
concentration detection limit of 0.039 pg/ml and 5.0 pg/ml,
respectively,  according  to  the  manufacturer’s  instructions.
Serum hsCRP concentrations were measured using the UBI
Magiwel  Enzyme  Immunoassay  (United  Biotech  Inc.,
Mountain View, CA) as per the manufacturer’s instructions.
The  assay  is  reported  to  have  a  minimum  detectable
concentration of 0.00035 mg/l.
Vitreous protein estimation: Vitreous protein (mg/ml) levels
were  estimated  by  the  bicinchoninic  acid  protein  assay
method  [25]  using  bicinchoninic  acid  reagent  (Sigma-
Aldrich, St. Louis, MO) containing 4% copper sulfate.
Statistical  analysis:  Age  and  sex  differences  between  the
patients and controls were investigated by the Student t test
and  chi-square  (χ2)  test,  respectively.  The  significance  of
difference of protein concentration between corresponding
groups of observations was evaluated by the Mann–Whitney
U  test  and  all  values  were  expressed  as  mean  (standard
deviation)  and  range.  The  correlations  between  study
parameters were analyzed by Spearman’s correlation test (by
GraphPad Software). The study groups were tested for the
Hardy–Weinberg  equilibrium  and  expected  and  observed
frequencies  were  compared  by  χ2  analysis  (by  an  online
calculator: provided by Tufts University, Boston, MA). The
allele and genotype frequencies for each SNP were compared
between ED patients and controls using the χ2 analysis on a
2×2 contingency table and calculation of the odds ratio with
a 95% confidence interval. Fischer’s exact p values were
calculated for analysis when one or more variables within the
2×2 tables were less than 5 (by online calculator provided in
the public domain by Vassar College, Poughkeepsie, NY).
Power calculation was conducted using PS Power and Sample
Size  Calculation  software  version  3.0.34.  The  Bonferroni
correction of the significance level was applied to account for
multiple testing. The level of statistical significance was set
at p<0.05, except for tests in which Bonferroni adjustment was
applied.
RESULTS
The  demographic  and  clinical  characteristics  of  the  study
participants are presented in Table 2. There was no significant
difference  in  age  (p=0.1424),  sex  (p=0.662),  ethnicity,  or
geographic  origin  between  the  ED  patients  and  healthy
controls whose SNP was analyzed as a whole.
Serum level of interleukin-6, high-sensitivity C-reactive
protein, and vascular endothelial growth factor, as well as
their  correlation  in  patients  with  Eales’  disease  in  the
inflammatory stage: Table 3 summarizes the demographic
and laboratory measurements of IL-6, hsCRP, and VEGF in
ED patients in the inflammatory stage of the disease (n=41)
TABLE 1. SEQUENCES OF PRIMERS AND PROBES USED FOR IL-6–174G/C GENOTYPING
Primer and probe name Sequence
Forward primer 5′-CGACCTAAGCTGCACTTTTCC-3‘
Reverse primer 5′-GGGCTGATTGGAAACCTTATTAAGATTG-3′
C-174 allele probe VIC-CCTTTAGCATgGCAAGAC
G-174 allele probe FAM-CCTTTAGCATcGCAAGAC
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2554and compared the values to those of the healthy controls
(n=223). There was no significant difference in age (p=0.09)
or sex (p=0.1750) between the selected group of patients and
healthy controls.
The mean serum concentration of IL-6 was higher in the
inflammatory stage in ED patients compared to the healthy
controls (27.21 pg/ml [7.56–78.12 pg/ml] versus 4.795 pg/ml
[1.04−10.56  pg/ml];  p<0.0001).  Similar  trends  were  also
observed for hsCRP (2.676 mg/l [1.670–3.987 mg/l] versus
0.9343 mg/l [0.56–1.43 mg/l]; p≤0.0001) and VEGF (308.8
pg/ml [136.3–410.4 pg/ml] versus 265.3 pg/ml (123.7–368.4
pg/ml]; p=0.0031).
Serum concentration of IL-6 significantly correlated with
serum hsCRP (Spearman’s correlation coefficient; r=0.4992,
p=0.0009) in the inflammatory stage in ED patients, but no
statistically significant correlation was seen between serum
IL-6  and  VEGF  (Spearman’s  correlation  coefficient;
r=0.08811, p=0.5838). Furthermore, no significant relation
between  VEGF  and  hsCRP  (Spearman’s  correlation
coefficient; r=0.2461, p=0.1208) was seen in the patients in
this stage (Figure 1).
No significant relation was found between serum IL-6
and  hsCRP  (Spearman’s  correlation  coefficient;  r=0.115,
p=0.2545)  or  VEGF  (Spearman’s  correlation  coefficient;
r=0.2198, p=0.1469), or between serum VEGF and hsCRP
(Spearman’s correlation coefficient; r=0.03568, p=0.8163) in
healthy controls.
Serum  levels  of  interleukin-6,  vascular  endothelial
growth factor, and high-sensitivity C-reactive protein, and
vitreous levels of IL-6 and vascular endothelial growth factor
in  patients  with  Eales’  disease  in  the  proliferative  stage:
Serum levels of IL-6 (2.017 pg/ml [1.3–2.98 pg/ml] versus
0.8886  pg/ml  [0.46–1.41  pg/ml];  p<0.0001)  and  VEGF
(324.96  pg/ml  [132.98–409.78  pg/ml]  versus  209.9  pg/ml
[32.45–398.78 pg/ml]; p=0.0105) were significantly higher in
ED patients in the proliferative stage who had undergone
vitrectomy compared to the control patients with macular
holes.  However,  no  significant  differences  were  found  in
serum  hsCRP  (1.02  mg/l  [0.658  −2.357  mg/l]  versus
0.9785 mg/l [0.623–1.41 mg/l]; p=0.81) level between these
two group (Table 4).
No significant correlation was found between the serum
concentration  of  IL-6  at  this  stage  of  ED  and  VEGF
(Spearman’s correlation coefficient; r=0.0470, p=0.689) or
hsCRP  (Spearman’s  correlation  coefficient;  r=0.3732,
p=0.1544).
Vitreous levels of IL-6 and VEGF were also significantly
higher in ED patients in the proliferative stage than in patients
TABLE 2. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE STUDY PARTICIPANTS
Characteristics ED patients (n=121) Controls
(n=223)
Control patients with macular
hole (n=16)
Males: Females 97:24 183:40 15:1
Mean age [years (SD)] 30.6 (10.7) 32.26 (9.6) 61.2 (7.5)
Type of lesion
Inflammatory stage
Active vasculitis in peripheral retina 41 - -
Proliferative stage
Neovascularization in the peripheral discs 50 - -
Vitreous hemorrhage with / without tractional retinal
detachment
30 - 16
Visual acuity
20/20 −20/40 38 212 -
20/50 – 20/70 23 11 -
20/80 – 20/100 30 - 6
20/200 – 20/400 30 - 10
TABLE 3. DEMOGRAPHIC AND LABORATORIES CHARACTERISTICS OF THE EALES DISEASE (ED) PATIENTS IN INFLAMMATORY STAGE AND HEALTHY
CONTROLS
Characteristics ED patients (inflammatory stage; n=41) Healthy controls (n=223) p value
Males: Females 29:12 183:40 0.09
Mean age [years (SD)] 30.1 (7.8) 32.26 (9.6) 0.175
Serum IL-6 (pg/ml) 27.21 (19.06) 4.795 (2.669) <0.0001*
Serum hsCRP (mg/l) 2.676 (0.6142) 0.9343(0.1455) <0.0001*
Serum VEGF (pg/ml) 308.8 (73.42) 265.3 (79.65) 0.0031*
Values are mean (SD) * Significant P value
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2555with macular holes (79.8 pg/ml [18.65–203.4 pg/ml] versus
12.53 pg/ml [2.32–65.36 pg/ml]; p<0.0001 and 1058.3 pg/ml
[750.98–1298.87 pg/ml] versus 16.987 pg/ml [6.98–65.87 pg/
ml]; p<0.0001). This difference remained at a significant level
when the ratio of IL-6 to vitreous protein (27.39 pg/mg versus
16.53 pg/mg; p=0.0071) and the ratio of VEGF to vitreous
protein (316.26 pg/mg versus 26.48 pg/mg; p=0.0001) were
considered (Table 4). We calculated the power of statistical
testing to establish the null hypothesis in the available vitreous
sample used in this study. There was a power of 100% to yield
a statistically significant result in this sample size.
There was no significant correlation between the vitreous
and serum levels of IL-6 (Spearman’s correlation coefficient;
r=0.2789, p=0.2475) and the vitreous and serum levels of
VEGF  (Spearman’s  correlation  coefficient;  r=0.2045,
p=0.4009) in patients in the proliferative stage of ED. Vitreous
concentrations of VEGF and IL-6 were significantly higher
than that obtained from the serum of ED patients (1058.3 pg/
ml versus 324.96 pg/ml; p=0.0001 and 79.8 pg/ml versus
2.017 pg/ml; p<0.0001). However, a statistically significant
directly proportional dependence was found between vitreous
concentration  of  IL-6  and  VEGF  (Spearman’s  correlation
coefficient; r=0.5834, p=0.0087) in ED patients (Figure 2).
Association  between  interleukin-6–174G/C  promoter
polymorphism and occurrence of Eales’ disease: Allele and
genotype  frequencies  of  IL-6-174G/C  promoter
polymorphisms were compared between ED patients (n=121)
and healthy controls (n=223); the results are presented in
Table 5. No significant departure from the Hardy–Weinberg
equilibrium was observed for the IL-6-174G/C variant in the
ED  patients  (χ2=3.29;  p=0.069)  or  the  healthy  controls
(χ2=0.357; p=0.549).
There  was  a  significant  difference  in  the  allelic
distribution  of  IL-6–174G/C  polymorphism  between  the
groups (p=0.01008), indicating that the −174G allele (85.53%
in ED patients versus 77.35% in controls) may be related to
ED occurrence. In addition, the −174C allele (14.46% in ED
patients versus 22.64% in controls) was found to be protective
against the occurrence of the disease. Individuals with the
−174GG  genotype  were  also  overrepresented  among  the
patients with ED as compared to controls (75.20% versus
60.53%,  p=0.006).  On  the  other  hand,  −174GC  genotype
frequency was significantly higher in healthy controls than in
the  ED  patients  (20.66%  versus  33.63%,  p=0.0114).  The
above  associations  remained  significant  after  Bonferroni
correction for multiple testing (0.0125; significance threshold
Figure 1. Relation between interleukin
(IL)-6  and  high-sensitivity  C-reactive
protein (hsCRP) or vascular endothelial
growth  factors  (VEGF)  in  the
inflammatory  stage  of  Eale’s  disease
(ED). A: The correlation between the
serum levels of interleukin-6 (IL-6) and
high-sensitivity  C-reactive  protein
(hsCRP) from 41 patients with Eales’
disease (ED) at the inflammatory stage.
The  IL-6  levels  in  serum  correlated
significantly with serum hsCRP levels
(Spearman’s  correlation  coefficient;
r=0.4992,  p=0.0009).  The  solid  line
represents the linear regression curve of
the best fit. B: The correlation between
the serum levels of IL-6 and vascular
endothelial growth factor (VEGF) from
41 patients with ED at the inflammatory
stage. No significant relation was seen
between serum IL-6 levels and serum
VEGF levels in the inflammatory stage
(Spearman’s  correlation  coefficient;
r=0.08811,  p=0.5838).  The  solid  line
represents the linear regression curve of
the best fit.
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2556after correction). We also calculated “power” to test the null
hypothesis. Based on the genotype GG homozygote, there is
a power of 79.2% to yield a statistically significant result in
this sample size.
Differential expression of interleukin-6, high-sensitivity
C-reactive protein, and vascular endothelial growth factor in
patients  and  controls  according  to  interleukin-6–174G/C
polymorphism: Figure 3 shows the distribution of serum IL-6,
hsCRP,  and  VEGF  concentrations  in  ED  patients  in  the
inflammatory stage and healthy controls in relation to each
-174G/C polymorphism. Mean serum concentrations of IL-6
were significantly higher in ED patients in the inflammatory
stage with the −174GG genotype than those with the −174GC
(45.75  pg/ml  versus  13.74  pg/ml;  p=0.0009)  or  −174CC
TABLE 4. DEMOGRAPHIC AND LABORATORIES CHARACTERISTICS OF THE EALES DISEASE (ED) PATIENTS IN PROLIFERATIVE STAGE (THOSE
UNDERWENT VITRECTOMY) AND CONTROLS PATIENTS WITH MACULAR HOLE UNDERWENT VITRECTOMY SURGERY
Characteristics ED patients (proliferative stage’ n=19) Control patients with macular
hole (n=16)
p value
Males: Females 18:0 15:1 0.4571
Mean age [years (SD)] 31.8 (8.1) 61.2 (7.5) 0.0001*
Serum IL-6 (pg/ml) 2.017 (0.5476) 0.8886 (0.2589) <0.0001*
Serum VEGF (pg/ml) 324.96 (91.34) 209.9 (98.475) 0.0105*
Serum hsCRP(mg/l) 1.02(0.685) 0.9785(0.268) 0.81
Vitreous IL-6 (pg/ml) 79.8 (48.53) 12.53 (8.57) <0.0001*
Vitreous VEGF (pg/ml) 1058.3 (181.5) 16.987 (14.836) <0.0001*
Vitreous protein (mg/ml) 3.482 (1.83) 0.695 (0.389) 0.0001*
Ratio of IL-6 to protein (pg/mg) 27.39 (12.86) 16.53 (8.65) 0.0071*
Ratio of VEGF to protein (pg/mg) 316.26 (106.32) 26.48 (13.26) 0.0001*
Values are mean (SD) * Significant P value
Figure 2. Correlation between vitreous
levels  of  interleukin-6  and  vascular
endothelial  growth  factor  from  19
patients  with  Eales’  disease  in  the
proliferative  stage.  The  interleukin-6
(IL-6) levels in vitreous were correlated
significantly  with  vitreous  vascular
endothelial  growth  factor  (VEGF)
levels  (Spearman’s  correlation
coefficient;  r=0.5834,  p=0.0087).  The
solid  line  represents  the  linear
regression curve of the best fit.
TABLE 5. ALLELE AND GENOTYPE FREQUENCIES OF INTERLEUKIN-6 (IL-6) GENE POLYMORPHISM IN EALES DISEASE (ED) CASES AND HEALTHY CONTROLS
IL-6 gene variants ED cases (n %) Healthy control (n %) p value OR (95% CL)
−174G/C Alleles
G 207(85.53) 345(77.35) 0.01008* 1.7314 (1.1362- 2.6386)
C 35(14.46) 101(22.64) 0.5776 (0.379- 0.8802)
Genotypes
GG 91(75.20) 135(60.53) 0.006* 1.9773 (1.2085- 3.2351)
GC 25(20.66) 75(33.63) 0.0114* 0.5139 (0.3054–0.8648)
CC 5(4.13) 13(5.82) 0.49 0.6963 (0.2422–2.0018)
        * Significant P- value after Bonferroni correction for multiple testing (i.e., the adjusted p value at the 0.05 significance level is
        0.0125)
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2557genotypes (45.75 pg/ml versus 10.68 pg/ml; p=0.0005). The
same trend was also observed in healthy controls. Patients at
this stage with the −174GG genotype had significantly higher
mean serum concentrations of hsCRP than those with the
−174GC  (3.172  mg/l  versus  1.941  mg/l;  p=0.0004)  or
−174CC genotype (3.172 mg/l versus1.87 mg/l; p=0.0004).
Mean hsCRP concentration in healthy controls with the GG
genotype  was  statistically  higher  than  in  those  with  CC
genotype (0.9723 mg/l versus 0.8475 mg/l; p=0.0063), but the
difference between the hsCRP concentration of controls with
the  GG  genotype  and  those  with  the  GC  genotype  was
statistically nonsignificant (0.9723 mg/l versus 0.9377 mg/l;
p=0.0562).  In  contrast,  the  mean  serum  concentration  of
VEGF  did  not  differ  significantly  in  patients  in  the
inflammatory stage of ED or healthy controls with different
−174G/C genotypes. There were significant differences in the
mean  serum  concentrations  of  IL-6,  hsCRP,  and  VEGF
between inflammatory-stage ED patients and healthy controls
for all three IL-6-174G/C genotypes (Table 6).
In the proliferative stage of ED, vitreous concentrations
of IL-6 and VEGF were significantly higher in patients with
the GG genotype than the GC genotype (101.5 pg/ml versus
42.58 pg/ml; p=0.0015 and 1151.0 pg/ml versus 899.0 pg/ml;
p=0.0067). We found no patients with the CC genotype in this
stage. Vitreous IL-6 concentration also showed a similar trend
in the case of control patients with macular holes. However,
vitreous VEGF concentration in control patients did not show
any significant variation with IL-6–174G/C polymorphism
(Figure 4) Mean vitreous concentrations of IL-6 and VEGF
were significantly higher in patients in the proliferative stage
than control patients with macular holes for all IL-6-174G/C
genotypes (Table 7).
DISCUSSION
ED is associated with localized inflammation of the retinal
blood vessel walls and is suggested to be an immune-mediated
disease.  Retinal  changes  include  periphlebitis,  peripheral
nonperfusion, and neovascularization. At the proliferative or
Figure 3. Serum protein concentration in study subjects according to −174G/C genotype. Serum concentrations of: A: interleukin-6 (IL-6),
B: high-sensitivity C-reactive protein (hsCRP), and C: vascular endothelial growth factor (VEGF) in patients with Eales’ disease (ED) at the
inflammatory stage, as well as the healthy controls, for each −174G/C genotype. The Mann–Whitney U test was performed to determine
whether significant differences were present within the same groups of subjects with different −174G/C genotypes. The results of this analysis
are indicated in brackets. An asterisk denotes a significant p value.
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2558advanced stage of the disease, newly formed retinal vessels
become  prone  to  developing  vitreous  hemorrhage,  thus
resulting in profound visual loss [4,6]. The impact of this
disease is profound because it remains one of the leading
causes of ocular morbidity on the Indian subcontinent and
affects patients in the most productive period of their life. In
light of the evidence linking inflammation and ED, it is of
interest to determine whether cytokines such as IL-6 and the
proposed involvement of IL-6 gene polymorphism in the in
vivo production of this protein illuminate the pathogenesis of
this disease.
In this report, we found that the patients in “active” or
inflammatory stage have elevated serum IL-6 levels. Whether
increased IL-6 merely reflects an acute phase reaction in these
patients was investigated by measuring circulating hsCRP
levels. CRP is a major acute phase reactant that is primarily
regulated by proinflammatory cytokines; it becomes elevated
in  response  to  a  variety  of  infections  and  inflammatory
conditions [26,27]. At the same time, CRP levels are rather
stable among healthy individuals and reflect the extent of
underlying systemic inflammation [28]. The hsCRP assay is
highly sensitive compared to measurement of basic CRP, thus
allowing patients who have low levels of inflammation to be
distinguished [26]. As compared to healthy controls, levels of
hsCRP increased more than twofold were found in ED patients
in the stage of active perivasculitis. Serum concentrations of
IL-6 are known to augment the production of CRP [10], which
may  also  reflect  the  significant  association  of  these  two
proteins in ED patients at this stage. In the inflammatory stage,
circulating  VEGF  concentrations  were  also  significantly
TABLE 6. MEAN SERUM CONCENTRATIONS INTERLEUKIN-6 (IL-6), HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), AND VASCULAR
ENDOTHELIAL GROWTH FACTOR (VEGF) IN EALES DISEASE (ED) PATIENTS AT INFLAMMATORY STAGE AND HEALTHY CONTROLS ACCORDING
TO –174G/C GENOTYPE
Genotype Patients (n=41) Controls (n=223) p value
IL-6 (pg/ml)
GG 45.75 (15.47) 6.026 (2.558) < 0.0001*
GC 13.74 (3.681) 2.906 (1.383) 0.0002*
CC 10.68 (2.836) 2.344 (0.9589) 0.0022*
hsCRP (mg/l)
GG 3.172 (0.5078) 0.9723 (0.1682) < 0.0001*
GC 1.941 (0.09016) 0.9377 (0.1615) 0.0002*
CC 1.87 (0.1382) 0.8475 (0.1065) 0.0018*
VEGF (pg/ml)
GG 324.2 (63.23) 251.6 (60.66) 0.0001*
GC 294.9 (50.47) 219.9 (28.7) 0.0335*
CC 270.1 (78.81) 207.1 (45.75) 0.0397*
              Values are mean (SD) * Significant P value
Figure 4. Vitreous protein concentration in study subjects according to −174G/C genotype. Vitreous concentrations of: A: interleukin-6 (IL-6)
and B: vascular endothelial growth factor (VEGF) in patients with Eales’ disease (ED) at the proliferative stage and control patients for each
−174G/C genotype. The Mann–Whitney U test was performed to determine whether significant differences were present within the same
groups of subjects with different −174G/C genotypes. The results of this analysis are indicated in brackets. An asterisk denotes a significant
p value.
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2559higher in ED patients compared to healthy controls, but serum
VEGF concentrations did not correlate with IL-6 or hsCRP.
From these data, it can be interpreted that in the inflammatory
stage  of  the  disease,  VEGF  synthesis  does  not  depend
specifically  on  IL-6,  but  is  rather  an  associated  effect  of
different proinflammatory cytokines that are secreted as a
response to some innate immune stimuli. In line with this
explanation, a link between proinflammatory cytokines and
VEGF was demonstrated for human peritoneal mesothelial
cells  in  vitro.  Incubation  of  mesothelial  cells  with
interleukin-1α (IL-1α), tumor necrosis factor-α, and thrombin
results in a significant increase in VEGF synthesis [29].
During  the  proliferative  stage  of  ED,  inflammation
subsided clinically which is also demonstrated by an almost
normal level of CRP in the serum of the patients, retinal
neovasculation  and  vitreous  hemorrhage  have  already
developed as a consequence of retinal hypoxia and ischemia
[14]. At this stage, the vitreous collected from ED patients
following  vitrectomy  is  a  unique  material  for  analysis  of
intraocular concentration and/or synthesis of several proteins
that orchestrate this pathology. However, the intravitreous
increase of a particular protein does not necessarily signal
intraocular production; it could reflect only the nonspecific
increase of total vitreal proteins observed in these patients,
which may be caused by the disruption of the blood–retinal
barrier.  In  this  regard,  we  analyzed  the  concentration  of
vitreous proteins that were higher in the ED patients than in
control  patients  with  macular  holes,  and  the  absolute
intravitreous concentration of IL-6 and VEGF were adjusted
by the total vitreal protein. In agreement with a previous study
[15], we found elevated intravitreous concentrations of IL-6
and VEGF in patients with ED in relation to control patients,
not only in absolute terms, but also after adjustment.
IL-6 has several roles in the neovascularization process.
It  can  increase  endothelial  cell  permeability  in  vitro  by
rearranging actin filaments and by changing the shape of
endothelial  cells  [30].  Furthermore,  IL-6  increases  the
expression of VEGF [17]. These reports, taken together with
our  results,  suggest  that  IL-6  may  promote  vascular
permeability along with VEGF in ED. On the other hand,
VEGF is a specific mitogen for vascular endothelial cell and
therefore has a central role in the physiologic, as well as
pathological, angiogenesis [19]. In the current study, vitreous
IL-6 level was significantly correlated with vitreous VEGF
concentration, thereby also supporting the known ability of
IL-6 to act as an indirect inducer of angiogenesis by inducing
VEGF expression [17].
The present study did not show any significant correlation
between intraocular and serum concentrations of IL-6 and
VEGF, and the vitreous concentrations of these factors are
significantly  higher  than  the  serum  concentrations  in  ED
patients. Therefore, these results reinforce the concept that the
intraocular  synthesis  of  IL-6  and  VEGF,  but  not  serum
diffusion  [15],  is  the  primary  cause  of  the  increased
intravitreous concentration of these parameters in ED patients.
Considering  the  pivotal  role  that  IL-6  plays  in  the
pathogenesis of ED, i.e., its role in modulating acute phase
inflammatory response during the inflammatory stage and
angiogenic  response  in  the  proliferative  stage,  there  is  a
possibility that differential IL-6 production may influence the
susceptibility and severity of ED. It has been established that
the constitutive levels of IL-6 are known to be genetically
controlled [22], but the putative influences of differential gene
expression products of IL-6 on ED onset remain unknown.
Within the IL-6 promoter region, one microsatellite and four
SNP have been investigated [31]. Among them, a common
functional G/C polymorphism located within the 5′ regulatory
sequence of the IL-6 gene at position −174 could affect IL-6
expression [22]. In the present study, we found a significant
association of the IL-6–174G allele, as well as the −174GG
genotype,  with  the  occurrence  of  ED.  In  contrast,  the
heterozygous GC genotype was significantly higher in the
controls and gives protection against ED occurrence. Thus, it
is suggested that the C allele has a masking effect over the G
allele in the heterozygous genotype; this may be due to a
complex  interaction  of  both  alleles  when  present
codominantly. Under such conditions, it is postulated that the
C  allele  induces  a  protective  response  that  prevents
TABLE 7. MEAN VITREOUS CONCENTRATIONS INTERLEUKIN-6 (IL-6) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN EALES
DISEASE (ED) PATIENTS AT PROLIFERATIVE STAGE AND CONTROL PATIENTS WITH MACULAR HOLE ACCORDING TO –174G/C GENOTYPE
Genotype Patients (n=19) Controls (n=16) p value
IL-6 (pg/ml)
GG 101.5 (48.34) 25.53 (26.59) 0.0023*
GC 42.58 (14.88) 5.415 (0.9661) 0.0061*
CC - 4.277 (1.263) -
VEGF (pg/ml)
GG 1151.0 (139.3) 22.91 (22.08) 0.0009*
GC 899.0 (127.8) 16.18 (10.33) 0.0106*
CC - 11.6 (5.607) -
               Values are mean (SD) * Significant p value.
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2560individuals from developing the disease. However, we did not
observe any significant association of the CC genotype with
the  onset  of  ED  or  with  a  protective  influence  against
development of ED.
In vitro studies revealed that the G allele of the −174 SNP
has been associated with an increased transcriptional response
against stimulation such as from endotoxin or interleukin-1β
[32], whereas studies investigating the role of the −174G/C
promoter polymorphism for the circulating IL-6 concentration
in  vivo  have  produced  conflicting  results.  According  to
Fishman et al. [22], unstimulated plasma IL-6 concentrations
were  associated  with  the  G  allele  in  healthy  individuals.
However,  others  have  reported  that  high  plasma  IL-6
concentrations  in  patients  and  healthy  individuals  were
associated with the C allele and CC genotype rather than with
the G allele and the GG or GC genotype [33]. Some studies
have also indicated that IL-6 −174G/C polymorphism does
not significantly affect plasma IL-6 concentrations [34,35].
We found that both ED and healthy controls with the GG
genotype had higher mean serum IL-6 concentrations than
those with the −174GC or −174CC genotypes.
Interestingly,  IL-6  G/C  promoter  polymorphism  has
functional significance [22]. The −174G/C polymorphism is
contained in a sequence bearing partial nucleotide homology
with the Sma- and Mad-related protein 4 (Smad4) binding
element. Smad4 is a transcription factor that participates in
the signal transduction cascade of transforming growth factor-
β and activin to inhibit the expression of proinflammatory
molecules [36]. The C allele at the variant position in the
consensus-binding  element  would  bind  Smad4  more
effectively,  and  hence  repress  IL-6  transcription,  while
substitution by a G-allele at this position decreases the binding
efficiency by 90% and therefore increases transcription of the
IL-6 gene [37]. Thus, the allele G at the −174 position of the
IL-6 gene may be a risk factor for ED manifestation associated
with constitutively high IL-6 concentration at the initial and
advanced stage of this disease.
It  was  of  interest  to  determine  whether  −174G/C
polymorphism may similarly affect the serum and/or vitreous
concentrations of proteins that are regulated by IL-6 in the
inflammatory and proliferative stages of ED. We found that
the −174GG genotype was associated with increased mean
serum concentrations of hsCRP patients in the inflammatory
stage of ED. The concentration of hsCRP in serum was also
observed to be higher in the −174GG genotype than in the CC
genotype  in  healthy  controls  in  our  population,  but  the
difference between hsCRP levels between healthy individuals
with the GG genotype and GC genotype was statistically
nonsignificant.  These  results  make  it  plausible  that  the
−174GG genotype facilitates increased IL-6 release, perhaps
due to some influence of innate immune response, in the initial
stage of ED, which causes the increased release of acute phase
inflammatory  proteins,  i.e.,  CRP.  This  possibility  is  also
supported by the observation that serum concentrations of
IL-6 and hsCRP in the inflammatory stage of ED patients, but
not in controls, correlate with one another. VEGF differed
from the CRP in this study because its concentrations were
independent of −174G/C polymorphism and not correlated
with IL-6 at the inflammatory stage of ED.
On the other hand, intravitreous concentrations of IL-6
and VEGF in patients, those that are representative of the
proliferative,  i.e.,  neovascularization  stage  of  ED,  are
significantly higher in the GG genotype than the GC genotype.
To compare, we also genotyped patients with macular holes,
those representing the control group for vitreous analysis, and
found  that  vitreous  IL-6  levels  but  not  VEGF  levels
significantly correlate with −174G/C polymorphism of the
IL-6  gene.  However,  it  is  not  significant  to  evaluate  any
correlation of the serum level of IL-6 or VEGF and −174G/C
polymorphism in the proliferative stage of ED, because in this
stage serum concentration does not influence the vitreous
levels of IL-6 and VEGF, and the role of vitreous in retinal
disorders is a matter of great interest.
In conclusion, it can be said that IL-6 acts as a regulator
of the inflammatory as well as the proliferative stage of ED
by  inducing  stage-specific  protein  expression.  IL-6
expression is directly regulated by the allelic distribution of
−174 loci and the enhanced level of IL-6 modulates CRP and
VEGF concentrations, respectively, depending on the acute
inflammatory stimulation at the initial stage and angiogenic
stimulation at the advanced stage of ED. To the best of our
knowledge, this is the first effort to investigate IL-6 gene
polymorphism and its role in the stage-specific modulation of
IL-6  and  consequently  VEGF  and  CRP  in  ED-affected
patients, and to provide a rationale for targeted therapeutic
investigation. The study of other functional polymorphisms
in the IL-6 gene will contribute to a better understanding of
the pathogenesis of ED, providing information that may have
diagnostic and therapeutic value in the future.
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